Published in Drug Week, November 15th, 2002
The fast track programs of the FDA are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.
ICA-17043 represents a novel approach to the treatment of sickle cell anemia by targeting a specific ion channel, known as the Gardos channel, located on the membrane of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week